Intervention

exemestane

ClinicalTrials.gov intervention label

Clinical trials52

Recruiting0

Common conditions25

Lead sponsors shown15

Clinical trials

52 shown

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast CancerNCT02820961 · 2016-06-29

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast CancerNCT02482753 · 2015-07-01

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsNCT02077933 · 2014-05-14

Breast Cancer, Sexuality and Black CohoshNCT02467686 · 2014-01-01

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast CancerNCT02007512 · 2013-12-16

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerNCT01674140 · 2013-09-12

ACTIVE_NOT_RECRUITING

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerNCT03176238 · 2013-03-29

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone TherapyNCT01720602 · 2012-11-01

Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung CancerNCT01664754 · 2012-09-07

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast CancerNCT01597193 · 2012-04-30

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast CancerNCT01385280 · 2011-02-01

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor TherapyNCT01153672 · 2010-11-01

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)NCT01234857 · 2010-09-17

ELBA: Exemestane and Lapatinib in Advanced Breast CancerNCT01005641 · 2009-12-01

Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer PatientsNCT01814397 · 2009-07-01

Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast CancerNCT00893061 · 2009-03-16

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast CancerNCT00931450 · 2009-03-01

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast CancerNCT00793546 · 2009-02-01

Exemestane in Treating Postmenopausal Women With Stage IV Breast CancerNCT00810797 · 2008-12-02

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)NCT00944918 · 2008-12-01

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast CancerNCT00719966 · 2008-09-18

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast CancerNCT00676663 · 2008-06-13

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast CancerNCT00674557 · 2008-06-01

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast CancerNCT00687648 · 2008-05-01

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor TherapyNCT00688194 · 2008-05-01

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast CancerNCT00902954 · 2008-03-01

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast CancerNCT00573755 · 2007-12-01

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast CancerNCT00417885 · 2007-06-01

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By SurgeryNCT00541086 · 2007-03-01

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast CancerNCT00372996 · 2007-02-01

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast CancerNCT00265759 · 2006-01-01

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast CancerNCT00194792 · 2005-08-01

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast CancerNCT00143390 · 2005-04-01

A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast CancerNCT00649090 · 2005-03-01

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast CancerNCT00083174 · 2004-12-03

Bioequivalency Study of Exemestane 25 mg Tablet Under Fed ConditionsNCT01331434 · 2004-10-01

Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsNCT01331421 · 2004-07-01

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsNCT01331447 · 2004-05-01

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast CancerNCT00066703 · 2003-11-03

Premenopausal Endocrine Responsive Chemotherapy TrialNCT00066807 · 2003-08-01

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast CancerNCT00066573 · 2003-06-06

Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast CancerNCT00057993 · 2002-07-01

Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal WomenNCT00040014 · 2002-06-01

Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast CancerNCT00279448 · 2002-01-01

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast CancerNCT00032136 · 2001-12-01

Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast CancerNCT00066586 · 2001-08-01

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of TamoxifenNCT00016432 · 2001-05-01

Adjuvant Post-Tamoxifen Exemestane TrialNCT00810706 · 2001-04-01

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast CancerNCT00010010 · 2000-06-01

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast CancerNCT00003418 · 1998-02-01

Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast CancerNCT00002777 · 1996-05-01

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast CancerNCT00080613

Common conditions

Leading sponsors

Pfizer9 NCIC Clinical Trials Group3 Roxane Laboratories3 University of Washington3 ETOP IBCSG Partners Foundation2 Gruppo Italiano Mammella (GIM)2 Mayo Clinic2 Novartis Pharmaceuticals2 Syndax Pharmaceuticals2 Alliance for Clinical Trials in Oncology1 AstraZeneca1 Cancer Research Campaign Clinical Trials Centre1 Cancer Research UK1 Centre Oscar Lambret1 Chipscreen Biosciences, Ltd.1

Trial status mix

COMPLETED32

TERMINATED9

UNKNOWN7

WITHDRAWN3

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE320

PHASE217

NA7

PHASE16

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.